Explore

Trendline Trendline
Click Therapeutics Secures $50M for Schizophrenia Digital Therapeutic

Click Therapeutics Secures $50M for Schizophrenia Digital Therapeutic

Click Therapeutics Secures $50M for Schizophrenia Digital Therapeutic
Trendline Trendline
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
Trendline Trendline
Amgen Advances Thyroid Eye Disease Treatment with New Subcutaneous TEPEZZA Data

Amgen Advances Thyroid Eye Disease Treatment with New Subcutaneous TEPEZZA Data

Amgen Advances Thyroid Eye Disease Treatment with New Subcutaneous TEPEZZA Data
Rapid Read Rapid Read
Utah's AI Prescription Pilot Raises Safety Concerns Amid Regulatory Scrutiny

Utah's AI Prescription Pilot Raises Safety Concerns Amid Regulatory Scrutiny

Utah's Office of Artificial Intelligence Policy has approved Doctronic, a health technology startup, to autonomously renew medical prescriptions using AI. This marks the first instance in the U.S. where AI is allowed to handle prescription renewals without direct physician oversight. The pilot program, which spans three phases, begins with physician review of every renewal and gradually reduces oversight to 5-10% of renewals. Concerns have been raised about the safety of this approach, especially after a security research firm demonstrated vulnerabilities in Doctronic's public-facing AI tool. The American Medical Association and the Utah Academy of Family Physicians have expressed objections, citing potential risks to patient safety. The program's design includes monthly reporting requirements and excludes controlled substances, but questions remain about whether AI systems should be regulated as medical devices by the FDA.
Trendline Trendline
ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury

ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury

ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury
Rapid Read Rapid Read
Ketamine's Antidepressant Mechanism Linked to Adenosine Surges

Ketamine's Antidepressant Mechanism Linked to Adenosine Surges

A recent study has identified adenosine surges as a key mechanism in the rapid antidepressant effects of ketamine. Unlike traditional antidepressants, which require weeks to take effect, ketamine induces immediate and long-lasting changes in mood by modulating adenosine receptors. This discovery challenges existing models of depression treatment and highlights the role of purinergic signaling in mood regulation. The study utilized advanced imaging and metabolic analysis to demonstrate how ketamine affects brain circuits, particularly in the medial prefrontal cortex.
Rapid Read Rapid Read
Nexalin Technology's Brain Stimulation Device Shows Promise in Reducing Self-Injury Among Adolescents

Nexalin Technology's Brain Stimulation Device Shows Promise in Reducing Self-Injury Among Adolescents

Nexalin Technology, Inc. has announced the publication of a peer-reviewed study in BMC Psychiatry, highlighting the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study focused on female adolescents with non-suicidal self-injury (NSSI) and reported statistically significant reductions in self-injury behaviors and depressive symptoms. The research involved six patients who underwent 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device. The findings indicated changes in brain-network activity and connectivity, particularly in emotional-control networks such as Default, Limbic, Salience/Ventral Attention, and Control networks. Improvements in anxiety and sleep quality were also noted, with no significant adverse effects reported, except for one mild headache that resolved quickly.
Trendline Trendline
Talkiatry Launches EMR Integration Tool for Psychiatric Referrals

Talkiatry Launches EMR Integration Tool for Psychiatric Referrals

Talkiatry Launches EMR Integration Tool for Psychiatric Referrals
Rapid Read Rapid Read
Therapists Urged to Screen Patients for AI Chatbot Use Amid Mental Health Concerns

Therapists Urged to Screen Patients for AI Chatbot Use Amid Mental Health Concerns

A new paper has been released urging therapists to routinely screen patients for their use of AI chatbots, particularly in the context of mental health support. The paper highlights the rapid and largely untested use of generative AI technologies for addressing mental health issues such as anxiety, depression, and relationship stress. Experts, supported by the World Health Organization, convened at a workshop at TU Delft to discuss the implications of AI chatbots in mental health care. They expressed concerns about the potential risks to well-being, especially among young people, and called for stronger governance and oversight in the use of these technologies.
Trendline Trendline
Compass Pathways Grants Equity Awards to New Employees Under Nasdaq Rule

Compass Pathways Grants Equity Awards to New Employees Under Nasdaq Rule

Compass Pathways Grants Equity Awards to New Employees Under Nasdaq Rule
Rapid Read Rapid Read
AI Integration in Mental Health Care Sparks Mixed Reactions

AI Integration in Mental Health Care Sparks Mixed Reactions

The integration of artificial intelligence (AI) in mental health care is generating a mix of fear, pushback, and enthusiasm among professionals. While AI tools are being adopted to improve efficiencies in documentation and administrative tasks, concerns about job replacement and the quality of care persist. A recent strike by mental health care providers at Kaiser Permanente highlighted these issues, as workers protested changes in triage systems that could pave the way for AI to replace human roles. Despite these concerns, experts like Dr. John Torous from Beth Israel Deaconess Medical Center believe AI will transform mental health care for the better, provided that clinicians are involved in the development and implementation of these technologies.
Rapid Read Rapid Read
Legion Health's AI System Approved to Prescribe Psychiatric Medication in Utah

Legion Health's AI System Approved to Prescribe Psychiatric Medication in Utah

Legion Health, a San Francisco-based startup, has received approval to use its AI application to prescribe psychiatric medications in Utah. The AI system is designed to renew prescriptions for specific medications such as fluoxetine (Prozac) and sertraline (Zoloft), which are used to treat anxiety and depression. The system is restricted to renewing prescriptions that were initially prescribed by a human psychiatrist, and it is only applicable to patients who are stable and have not been hospitalized for psychiatric conditions in the past year. Despite these limitations, experts express concerns about the potential for over-treatment and the system's ability to accurately assess patient needs. The AI system is part of a broader effort to address mental health care shortages in Utah, with the company planning to expand the service nationwide by the end of the year.